Grant of Interim Extension of the Term of U.S. Patent No. 7,199,162; GRAFAPEXTM (Treosulfan), 71533-71534 [2023-22836]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices
written statements at any time before or
after the meeting. However, to facilitate
distribution of public presentation
materials to Committee members, the
Committee suggests that presenters
forward the public presentation
materials prior to the meeting to Ms.
Springer.
The Assistant Secretary for
Administration, with the concurrence of
the delegate of the General Counsel,
formally determined on January 3, 2023,
pursuant to 5 U.S.C. 1009(d) of the
FACA, that the portion of the meeting
dealing with pre-decisional changes to
the Commerce Control List and the U.S.
export control policies shall be exempt
from the provisions relating to public
meetings found in 5 U.S.C. 1009(a)(1)
and 1009(a)(3). The remaining portions
of the meeting will be open to the
public.
For more information, contact Ms.
Springer via email.
Yvette Springer,
Committee Liaison Officer.
[FR Doc. 2023–22893 Filed 10–16–23; 8:45 am]
BILLING CODE 3510–JT–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
[RTID 0648–XD464]
North Pacific Fishery Management
Council; Public Meeting
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice of hybrid meeting.
AGENCY:
The North Pacific Fishery
Management Council (Council) Bering
Sea Fishery Ecosystem Plan Climate
Change Taskforce (BSFEP CC) will meet
November 1, 2023 through November 2,
2023.
DATES: The meeting will be held on
Wednesday, November 1, 2023, from 1
p.m. to 5 p.m. and on Thursday,
November 2, 2023, from 9 a.m. to 5
p.m., Pacific time.
ADDRESSES:
Meeting address: The meeting will be
a hybrid meeting. The in-person
component of the meeting will be held
at the Alaska Fishery Science Center in
Room 2079, 7600 Sand Point Way NE,
Building 4, Seattle, WA 98115.
If you plan to attend in-person you
need to notify Diana Stram
(diana.stram@noaa.gov) at least two
days prior to the meeting (or two weeks
prior if you are a foreign national). You
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:02 Oct 16, 2023
Jkt 262001
will also need a valid U.S. Identification
Card. If you are attending virtually, join
the meeting online through the link at
https://meetings.npfmc.org/Meeting/
Details/3016.
Council address: North Pacific
Fishery Management Council, 1007 W
3rd Ave., Suite 400, Anchorage, AK
99501–2252; telephone: (907) 271–2809.
Instructions for attending the meeting
are given under SUPPLEMENTARY
INFORMATION, below.
Dr.
Diana Stram, Council staff; phone; (907)
271–2809 and email: diana.stram@
noaa.gov. For technical support, please
contact our administrative staff; email:
npfmc.admin@noaa.gov.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
Agenda
Wednesday, November 1, 2023, Through
Thursday, November 2, 2023
The agenda will include: (a) an
overview on Climate ecosystems and
fisheries initiative; (b) overview on IRA
funding; (c) overview of Alaska Climate
Integrated Modeling and Alaska
Dashboard Adaptation Planning Tools;
(d) summary of CCTF member survey
feedback on climate scenario planning
workshop plans; (e) recommended
approach for Climate Scenario Planning
Workshop; (f) research priorities; (g)
future plans; and (h) and other business.
The agenda is subject to change, and the
latest version will be posted at https://
meetings.npfmc.org/Meeting/Details/
3016 prior to the meeting, along with
meeting materials.
Connection Information
You can attend the meeting online
using a computer, tablet, or smart
phone; or by phone only. Connection
information will be posted online at:
https://meetings.npfmc.org/Meeting/
Details/3016.
Public Comment
Public comment letters will be
accepted and should be submitted
electronically to https://meetings.
npfmc.org/Meeting/Details/3016.
Authority: 16 U.S.C. 1801 et seq.
Dated: October 11, 2023.
Rey Israel Marquez,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2023–22827 Filed 10–16–23; 8:45 am]
BILLING CODE 3510–22–P
PO 00000
Frm 00007
Fmt 4703
Sfmt 4703
71533
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2021–0052]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,199,162;
GRAFAPEXTM (Treosulfan)
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,199,162
(‘162 patent).
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, at 571–
272–7728 or raul.tamayo@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period (RRP) is reasonably expected to
extend beyond the expiration date of the
patent.
On August 28, 2023, Medac
Gesellschaft fuer Klinische
Spezialpraparate mbH, the owner of
record of the ‘162 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term
of the ‘162 patent. The ‘162 patent
claims a method of using the human
drug product known by the tradename
GRAFAPEXTM (treosulfan). The
application for interim patent term
extension indicates that a RRP as
described in 35 U.S.C. 156(g)(1)(B)(ii)
began for GRAFAPEXTM (treosulfan)
and is ongoing before the Food and Drug
Administration for permission to market
and use the product commercially.
Review of the interim patent term
extension application indicated that,
except for permission to market or use
the product commercially, the ‘162
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it was apparent that
the RRP would continue beyond the
twice-extended expiration date of the
‘162 patent, i.e., October 12, 2023, a
third interim extension of the patent
term under 35 U.S.C. 156(d)(5) was
appropriate.
SUMMARY:
E:\FR\FM\17OCN1.SGM
17OCN1
71534
Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 7,199,162 was granted on
October 10, 2023, for a period of one
year from the twice-extended expiration
date of the ‘162 patent.
Brian Hanlon,
Acting Deputy Commissioner for Patents,
United States Patent and Trademark Office.
[FR Doc. 2023–22836 Filed 10–16–23; 8:45 am]
BILLING CODE 3510–16–P
CONSUMER FINANCIAL PROTECTION
BUREAU
Supervisory Highlights Junk Fees
Update Special Edition, Issue 31, Fall
2023
Consumer Financial Protection
Bureau.
ACTION: Supervisory Highlights.
AGENCY:
The Consumer Financial
Protection Bureau (CFPB or Bureau) is
issuing its thirty first edition of
Supervisory Highlights.
DATES: The findings included in this
report cover examinations in the areas
of deposits, auto servicing, and
remittances that generally were
completed between February 2023 and
August 2023. The report also describes
risks identified in connection with
payment platforms that parents,
guardians, and students use to pay for
school lunches.
FOR FURTHER INFORMATION CONTACT:
Jaclyn Sellers, Senior Counsel, at (202)
435–7449. If you require this document
in an alternative electronic format,
please contact CFPB_Accessibility@
cfpb.gov.
SUPPLEMENTARY INFORMATION:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
1. Introduction
As part of its emphasis on fair
competition, the Consumer Financial
Protection Bureau (CFPB) has launched
an initiative, consistent with its legal
authority, to scrutinize junk fees
charged by banks and financial
companies. Junk fees are typically not
subjected to the normal forces of
competition, leading to excessive costs
for services that a consumer may not
even want. For example, certain banks
and financial companies might hide
these unavoidable or surprise charges or
disclose them only at a later stage in the
consumer’s purchasing process, if at all.
The CFPB has observed that
supervised institutions have started to
compete more when it comes to fees. In
recent years, multiple banks have
announced they were eliminating
overdraft fees or otherwise updating
VerDate Sep<11>2014
17:02 Oct 16, 2023
Jkt 262001
their policies to be more consumer
friendly.1 And many have announced
that they are eliminating non-sufficient
fund (NSF) fees on consumer deposit
accounts.2
Supervision continues to focus
significant resources on identifying and
eliminating junk fees charged by
supervised institutions. Significantly,
financial institutions are refunding over
$120 million to consumers for
unanticipated overdraft fees and unfair
NSF fees. This special edition of
Supervisory Highlights updates the
public on supervisory work completed
since the CFPB published the March
2023 Supervisory Highlights Junk Fees
Special Edition. In total, for the topics
covered in this edition, Supervision’s
work has resulted in institutions
refunding over $140 million to
consumers.
The findings included in this report
cover examinations in the areas of
deposits, auto servicing, and
remittances that generally were
completed between February 2023 and
August 2023.3 The report also describes
risks identified in connection with
payment platforms that parents,
guardians, and students use to pay for
school lunches. Additionally, consistent
with the statutory requirement for
Supervision to identify and consider
‘‘risks to consumers’’ throughout its
supervisory program, Supervision has
obtained data about certain deposit
account fee practices and is sharing key
data points that shed light on risks to
consumers. To maintain the anonymity
of the supervised institutions discussed
in Supervisory Highlights, references to
institutions generally are in the plural
and related findings may pertain to one
or more institutions.
We invite readers with questions or
comments about Supervisory Highlights
to contact us at CFPB_Supervision@
cfpb.gov.
2. Supervisory Observations
2.1 Deposits
In recent examinations of depository
institutions and service providers,
Supervision has reviewed certain fees
related to deposit accounts to assess
whether supervised entities have
1 Banks’ Overdraft/NSF Fee Revenues Evolve
Along With Their Policies, (July 20, 2023), available
at: https://www.consumerfinance.gov/about-us/
blog/banks-overdraft-nsf-fee-revenues-evolve-alongwith-their-policies/. Some banks have announced
significant changes while others have made smaller
or no changes.
2 Id.
3 If a supervisory matter is referred to the Office
of Enforcement, Enforcement may cite additional
violations based on these facts or uncover
additional information that could impact the
conclusion as to what violations may exist.
PO 00000
Frm 00008
Fmt 4703
Sfmt 4703
engaged in any unfair, deceptive, or
abusive acts or practices (UDAAPs)
prohibited by the Consumer Financial
Protection Act of 2010 (CFPA).4
Examiners have focused on NSF and
overdraft fees in particular and have
reviewed statement fees and surprise
depositor fees as well. Examiners also
have engaged in follow-up work
regarding pandemic relief benefits.
2.1.1 Assessing Multiple NSF Fees for
the Same Transaction
Supervision continued examinations
of institutions to review for UDAAPs in
connection with charging consumers
NSF fees, especially with respect to ‘‘representments.’’ 5 A re-presentment
occurs when, after declining a
transaction because of insufficient funds
and assessing an NSF fee for the
transaction, the consumer’s accountholding institution returns the
transaction to the merchant’s depository
institution, and the merchant presents
the same transaction to the consumer’s
account-holding institution for payment
again. In some instances, when the
consumer’s account remains insufficient
to pay for the transaction upon representment, the consumer’s accountholding institution again returns the
transaction to the merchant and assesses
another NSF fee for the transaction,
without providing consumers a
reasonable opportunity to prevent
another fee after the first failed
presentment attempt. Absent
restrictions on the assessment of NSF
fees by the consumer’s account-holding
institution, this cycle can occur
multiple times, and consumers may be
charged multiple fees for a single
transaction.
Core Processor Practices
Core processors provide critical
deposit, payment, and data processing
services to many supervised
institutions, and the system
functionality that these entities develop
drives many fee practices, including
NSF fee practices. Supervision has
examined core processors in their
capacity as service providers to covered
persons providing deposit services.
Examiners concluded that, in the
offering and providing of core service
platforms, core processors engaged in an
unfair act or practice by contributing to
the assessment of unfair NSF fees on represented items. An act or practice is
4 12
U.S.C. 5531(c), 5536.
depository institutions charge a NSF fee
when a consumer pays for a transaction with a
check or an ACH transfer and the transaction is
presented for payment, but there is not a sufficient
balance in the consumer’s account to cover the
transaction.
5 Some
E:\FR\FM\17OCN1.SGM
17OCN1
]]>Agencies
[Federal Register Volume 88, Number 199 (Tuesday, October 17, 2023)]
[Notices]
[Pages 71533-71534]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-22836]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2021-0052]
Grant of Interim Extension of the Term of U.S. Patent No.
7,199,162; GRAFAPEX\TM\ (Treosulfan)
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 7,199,162 (`162 patent).
FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor,
Office of Patent Legal Administration, at 571-272-7728 or
[email protected].
SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the
term of a patent may be extended for a period of up to five years, if
the patent claims a product, or a method of making or using a product,
that has been subject to certain defined regulatory review. 35 U.S.C.
156(d)(5) generally provides that the term of such a patent may be
extended for no more than five interim periods of up to one year each,
if the approval phase of the regulatory review period (RRP) is
reasonably expected to extend beyond the expiration date of the patent.
On August 28, 2023, Medac Gesellschaft fuer Klinische
Spezialpraparate mbH, the owner of record of the `162 patent, timely
filed an application under 35 U.S.C. 156(d)(5) for a third interim
extension of the term of the `162 patent. The `162 patent claims a
method of using the human drug product known by the tradename
GRAFAPEXTM (treosulfan). The application for interim patent
term extension indicates that a RRP as described in 35 U.S.C.
156(g)(1)(B)(ii) began for GRAFAPEXTM (treosulfan) and is
ongoing before the Food and Drug Administration for permission to
market and use the product commercially.
Review of the interim patent term extension application indicated
that, except for permission to market or use the product commercially,
the `162 patent would be eligible for an extension of the patent term
under 35 U.S.C. 156. Because it was apparent that the RRP would
continue beyond the twice-extended expiration date of the `162 patent,
i.e., October 12, 2023, a third interim extension of the patent term
under 35 U.S.C. 156(d)(5) was appropriate.
[[Page 71534]]
A third interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 7,199,162 was granted on October 10, 2023, for a period
of one year from the twice-extended expiration date of the `162 patent.
Brian Hanlon,
Acting Deputy Commissioner for Patents, United States Patent and
Trademark Office.
[FR Doc. 2023-22836 Filed 10-16-23; 8:45 am]
BILLING CODE 3510-16-P
